Loading…
TherapeuticsMD, Inc. is projected to rise to $2.26 by 2027, a +11% move from its current price of $2.04. TXMD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.99 | $2.04 | $2.09 | +0.03% |
| Aug 6 | $1.97 | $2.04 | $2.11 | +0.05% |
| Aug 7 | $1.95 | $2.04 | $2.13 | +0.08% |
| Aug 8 | $1.94 | $2.04 | $2.15 | +0.10% |
| Aug 9 | $1.93 | $2.04 | $2.16 | +0.13% |
| Aug 10 | $1.92 | $2.04 | $2.17 | +0.15% |
| Aug 11 | $1.91 | $2.04 | $2.18 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.91 | $2.04 | $2.18 | +0.18% |
| Week 2 | $1.86 | $2.05 | $2.25 | +0.35% |
| Week 3 | $1.83 | $2.05 | $2.30 | +0.53% |
| Week 4 | $1.80 | $2.05 | $2.35 | +0.71% |
| Week 5 | $1.77 | $2.06 | $2.39 | +0.89% |
| Week 6 | $1.75 | $2.06 | $2.43 | +1.07% |
| Week 7 | $1.73 | $2.07 | $2.46 | +1.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its description highlights a portfolio of branded therapies and related prescription vitamins, and it functions within the Healthcare category as a pharmaceuticals-focused business.
Its product lineup includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus, and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under BocaGreenMD and vitaMedMD, and maintains a license agreement with Mayne Pharma Group Limited. Products are sold through wholesale distributors and retail pharmacy distributors.
TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
TXMD is currently priced at $2.11 per share, with a market capitalization of $24.42M and a rank of 4521. The stock trades in a market where the forecast implies upside over time, reflecting a path from a 2026 avg of $2.11 to a 2050 avg of $15.62 and a 2050 max of $30.62. The 30-day technical picture shows near-term support and resistance levels that frame the current price action.
Current price and market position set the stage for a longer horizon forecast, which projects a series of higher-average prices across years, culminating in a much higher long-run potential. These figures are estimates and reflect potential movement over time but are not guarantees.
Overall, the outlook suggests potential upside from the current level, with yearly averages rising from the low twos toward the mid-teens by 2050, while acknowledging the inherent uncertainty in any long-range forecast.
A major floor 13.2% below — a decisive break under it would weaken the trend.
The nearest floor, 4.9% below — buyers have tended to step in here.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 16.2% above — clearing it would confirm fresh momentum.
Key TXMD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TXMD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.05 | Sell | $2.04 | Sell |
| MA 10 | $2.05 | Sell | $2.04 | Sell |
| MA 20 | $2.02 | Buy | $2.04 | Sell |
| MA 50 | $2.05 | Sell | $2.05 | Sell |
| MA 100 | $2.08 | Sell | $2.04 | Sell |
| MA 200 | $1.96 | Buy | $1.93 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.25 | Neutral |
| Stoch RSI (14) | 46.52 | Neutral |
| CCI (20) | 14.11 | Neutral |
| Williams %R (14) | -47.06 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 4.64 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 52.94 | Neutral |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 55.65 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 2.04 | Sell |
| ADX (14) | 7.46 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is bullish in sentiment. RSI(14) sits at 60, with the 50-day simple moving average at $2.04 and the 200-day simple moving average at $1.92, signaling near-term momentum supportive of the price level.
The stock is trading near a near-term price range, with a 30-day range of $1.71 to $2.60 and a near-term technical setup framed by a support at $1.82 and a resistance at $2.29. Annualized volatility runs at 60%, highlighting meaningful price movement potential within the month.
These technical markers suggest buyers are active around the present level, while upside resistance caps further near-term gains.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.65 | $2.04 | $2.72 | 0% | Neutral | |
| $1.82 | $2.26 | $2.97 | +11% | Neutral | |
| $2.03 | $2.59 | $3.52 | +27% | Bullish | |
| $2.43 | $3.17 | $4.42 | +55% | Bullish | |
| $2.71 | $3.60 | $5.14 | +76% | Bullish | |
| $2.68 | $3.62 | $5.27 | +77% | Bullish | |
| $2.76 | $3.79 | $5.62 | +86% | Bullish | |
| $2.89 | $4.03 | $6.08 | +98% | Bullish | |
| $2.90 | $4.10 | $6.27 | +101% | Bullish | |
| $3.42 | $4.90 | $7.60 | +140% | Bullish | |
| $4.08 | $6.20 | $10.19 | +204% | Bullish | |
| $8.41 | $14.16 | $25.37 | +594% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.65 | $2.04 | $2.52 | +0.00% |
| September 2026 | $1.80 | $2.12 | $2.57 | +4.05% |
| October 2026 | $1.76 | $2.09 | $2.55 | -1.64% |
| November 2026 | $1.79 | $2.13 | $2.63 | +2.02% |
| December 2026 | $1.82 | $2.19 | $2.72 | +2.66% |
Click any year to see its month-by-month TXMD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TXMD could reach as high as $2.72, with a base case around $2.04 and support toward $1.65 — roughly 0% from $2.04. Price action looks broadly range-bound.
Expect TXMD to range from $1.82 to $2.97 through 2027. The $2.26 average target implies a +11% move from current prices. That is up +11% on the projected 2026 average. A consolidation phase looks the most probable path here.
The TXMD price prediction for 2028 points to an average of $2.59 (low $2.03, high $3.52) — a potential gain of +27% on today's $2.04. Momentum favours further upside here.
In 2029, TXMD is projected to trade between $2.43 and $4.42, averaging $3.17 — a potential gain of +55% from today's $2.04. That is up +22% on the projected 2028 average. Buyers look set to stay in control over this stretch.
TherapeuticsMD, Inc.'s 2030 outlook centres on $3.60, within a $2.71 to $5.14 range. That is up +14% on the projected 2029 average. That marks a +76% change versus current levels. Momentum favours further upside here.
By 2031, TXMD could reach as high as $5.27, with a base case around $3.62 and support toward $2.68 — roughly +77% from $2.04. Buyers look set to stay in control over this stretch.
Expect TXMD to range from $2.76 to $5.62 through 2032. The $3.79 average target implies a +86% move from current prices. That is up +5% on the projected 2031 average. Momentum favours further upside here.
The TXMD price prediction for 2033 points to an average of $4.03 (low $2.89, high $6.08) — a potential gain of +98% on today's $2.04. Buyers look set to stay in control over this stretch.
In 2034, TXMD is projected to trade between $2.90 and $6.27, averaging $4.10 — a potential gain of +101% from today's $2.04. That is up +2% on the projected 2033 average. Momentum favours further upside here.
TherapeuticsMD, Inc.'s 2035 outlook centres on $4.90, within a $3.42 to $7.60 range. That is up +20% on the projected 2034 average. That marks a +140% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, TXMD could reach as high as $10.19, with a base case around $6.20 and support toward $4.08 — roughly +204% from $2.04. Momentum favours further upside here.
Expect TXMD to range from $8.41 to $25.37 through 2050. The $14.16 average target implies a +594% move from current prices. That is up +129% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TXMD today (≈ 490.196078 TXMD) could be worth
$6,941.33
+$5,941.33 (+594%) by 2050 · US Dollar
Based on the average projected TXMD price of $14.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TXMDwould be worth at today's price.
$1,000 invested in TXMD on Jul 31, 2025 (≈ 892.857139 TXMD) would be worth
$1,821.43
+$821.43 (+82.1%) today · 1.82× · US Dollar
Based on a TXMD entry price of $1.12 vs. today's $2.04.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.06 | $990.29 | -1.0% |
| 1 month ago | $2.16 | $944.44 | -5.6% |
| 3 months ago | $2.07 | $985.51 | -1.4% |
| 6 months ago | $2.26 | $902.65 | -9.7% |
| 1 year ago | $1.12 | $1,821.43 | +82.1% |
| All time (5.0y) ago | $47 | $43.4 | -95.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TXMD forecast.
Our base-case forecast reaches $4.10 around 2035.
Implied market cap at $4.10: $47.45M
The long-term forecast lays out a multi-year ascent in the average price, with 2026 at an avg of $2.11 and a max of $2.88, then rising through 2027 ($2.29 avg, $3.10 max) and 2028 ($2.82 avg, $3.98 max) as bullish momentum builds. By 2029 the avg is $3.45 with a max of $5.04, and by 2030 the avg reaches $3.89 with a max of $5.84, marking a strong upward trajectory (84.4% ROI) and a bullish sentiment.
The ascent continues across years, with 2031 at $3.97 avg and 2032 at $4.02 avg, both bullish; 2033 at $4.28 avg and 2034 at $4.40 avg. The 2035 forecast shows a larger jump to $5.28 avg and a max of $8.75, reflecting a 150.3% ROI and bullish sentiment. In the deeper horizon, 2040 projects an avg of $6.68 with a max of $11.86 (216.7% ROI), and 2050 projects an avg of $15.62 with a max of $30.62 (640.3% ROI), continuing to be rated bullish.
Overall, the forecast depicts a steady, bullish progression across the long term, anchored by higher yearly averages and sizable potential upside in the 2040–2050 window. The numbers represent estimates rather than guarantees, and uncertainty remains in any long-range projection.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $3.89 with a min of $2.80 and a max of $5.84, and a bullish sentiment. The ROI is projected at 84.4% in 2030.
The forecast trend turns bullish from 2028 onward, with 2035 at $5.28 avg and 2040 at $6.68 avg, rising to 2050 at $15.62 avg. The implied ROI grows to 640.3% by 2050, but these are estimates and carry uncertainty.
Yes. The 2040 max is $11.86 and the 2050 max is $30.62, indicating the possibility of reaching and exceeding $10 by 2040 or later.
The current price is $2.11 per share, and the market capitalization is $24.42M.
The 30-day range is $1.71 to $2.60.
TherapeuticsMD, Inc. Community Discussion
0Share your TherapeuticsMD, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.